HUP0204243A3 - Novel helicobacter pylori-binding substances and use thereof - Google Patents

Novel helicobacter pylori-binding substances and use thereof

Info

Publication number
HUP0204243A3
HUP0204243A3 HU0204243A HUP0204243A HUP0204243A3 HU P0204243 A3 HUP0204243 A3 HU P0204243A3 HU 0204243 A HU0204243 A HU 0204243A HU P0204243 A HUP0204243 A HU P0204243A HU P0204243 A3 HUP0204243 A3 HU P0204243A3
Authority
HU
Hungary
Prior art keywords
helicobacter pylori
binding substances
novel helicobacter
novel
substances
Prior art date
Application number
HU0204243A
Other languages
English (en)
Original Assignee
A & Science Invest Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A & Science Invest Ab filed Critical A & Science Invest Ab
Publication of HUP0204243A2 publication Critical patent/HUP0204243A2/hu
Publication of HUP0204243A3 publication Critical patent/HUP0204243A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016Disaccharides, e.g. lactose, lactulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/105Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HU0204243A 1999-12-15 2000-12-15 Novel helicobacter pylori-binding substances and use thereof HUP0204243A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9904581A SE9904581D0 (sv) 1999-12-15 1999-12-15 A novel helicobacter pylori-binding substance and use thereof
PCT/SE2000/002567 WO2001043751A1 (en) 1999-12-15 2000-12-15 Novel helicobacter pylori-binding substances and use thereof

Publications (2)

Publication Number Publication Date
HUP0204243A2 HUP0204243A2 (hu) 2003-03-28
HUP0204243A3 true HUP0204243A3 (en) 2003-08-28

Family

ID=20418126

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0204243A HUP0204243A3 (en) 1999-12-15 2000-12-15 Novel helicobacter pylori-binding substances and use thereof

Country Status (18)

Country Link
US (1) US20040086514A1 (hu)
EP (1) EP1237558A1 (hu)
JP (1) JP2003517015A (hu)
CN (1) CN100389773C (hu)
AU (1) AU783876B2 (hu)
CA (1) CA2392766A1 (hu)
CZ (1) CZ20021989A3 (hu)
EE (1) EE200200312A (hu)
HU (1) HUP0204243A3 (hu)
IL (1) IL150247A0 (hu)
NO (1) NO20022890L (hu)
NZ (1) NZ520111A (hu)
PL (1) PL356329A1 (hu)
RU (1) RU2283115C2 (hu)
SE (1) SE9904581D0 (hu)
SK (1) SK8152002A3 (hu)
WO (1) WO2001043751A1 (hu)
ZA (1) ZA200204251B (hu)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904581D0 (sv) * 1999-12-15 1999-12-15 A & Science Invest Ab A novel helicobacter pylori-binding substance and use thereof
FI20010118A (fi) * 2001-01-19 2002-07-20 Carbion Oy Uudet helicobacter pylori reseptorit ja niiden käyttö
US20040176320A1 (en) * 2001-06-29 2004-09-09 Jari Natunen Use of at least one glycoinhibitor substance
FI20011403A (fi) * 2001-06-29 2002-12-30 Carbion Oy Menetelmä ja koostumukset vatsan sairauksien hoitoon
US20050220819A1 (en) * 2002-01-18 2005-10-06 Biotie Therapies Oyj Novel binding epitopes for helicobacter pylori and use thereof
US6946451B2 (en) 2002-02-04 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Insulin secretion promoter
ATE428430T1 (de) * 2002-06-28 2009-05-15 Glykos Finland Oy Therapeutische zusammensetzungen zur verwendung bei der prophylaxe oder behandlung von durchfall
FI20021989A0 (fi) * 2002-11-06 2002-11-06 Halina Miller-Podraza Korkean affiniteetin Helicobacter pylori-reseptorit ja niiden käyttö
WO2006094267A2 (en) * 2005-03-03 2006-09-08 Indiana University Research And Technology Corporation Permethylation of oligosaccharides
JP4677525B2 (ja) * 2005-08-23 2011-04-27 国立大学法人 長崎大学 ヘリコバクター・ピロリの空胞化毒素の検出試薬および検出方法
FR2906808B1 (fr) * 2006-10-10 2012-10-05 Univ Nantes Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers
JP5014018B2 (ja) * 2006-10-18 2012-08-29 旭化成ケミカルズ株式会社 ピロリ菌の抑制剤または静菌剤
JP4811953B2 (ja) 2007-01-12 2011-11-09 公益財団法人野口研究所 α−N−アセチルグルコサミニル結合単糖誘導体を含有するピロリ菌増殖抑制剤
EP2060257A1 (en) 2007-11-08 2009-05-20 Nestec S.A. Prevention and treatment of secondary infections following viral infection
GB0817908D0 (en) * 2008-10-01 2008-11-05 Univ Ghent Blood group a/b/h determinant on type 1 core glycosphinglipids chain as recognition point for the fedf protein of f18-fimbriated enterotoxigenic
WO2010041746A1 (ja) * 2008-10-10 2010-04-15 財団法人野口研究所 ピロリ菌増殖抑制剤
WO2013164652A2 (en) * 2012-05-04 2013-11-07 Ineb-Instituto De Engenharia Biomédica Microspheres

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1544908A (en) * 1975-07-08 1979-04-25 Chembiomed Ltd Artificial oligosaccharide antigenic determinants
JPS57500609A (hu) * 1980-05-09 1982-04-08
US4678747A (en) * 1983-02-18 1987-07-07 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies for detection of an H (O) blood group antigen
SE8304006D0 (sv) * 1983-07-15 1983-07-15 Karlsson Karl Anders Forening och komposition for terapeutisk eller diagnostisk anvendning samt forfarande for terapeutisk behandling
DK17885D0 (da) * 1985-01-14 1985-01-14 Karlsson Karl Anders Antiviralt middel
US4971905A (en) * 1987-08-11 1990-11-20 Pacific Northwest Research Foundation Diagnosis of cancerous or precancerous conditions in human secretory epithelia by enzyme activity of β-1-3N-acetylglucosaminyltransferase
US4895838A (en) * 1988-03-09 1990-01-23 Trustees Of Boston University Method for provoking angiogenesis by administration of angiogenically active oligosaccharides
US4957741A (en) * 1988-08-02 1990-09-18 Angio-Medical Corp. Method for the treatment of gastric ulcer
MX9304638A (es) * 1992-07-31 1994-05-31 Neose Pharm Inc Composicion para tratar e inhibir las ulceras gastricas y duodenales.
US6406894B1 (en) * 1992-12-11 2002-06-18 Glycorex Ab Process for preparing polyvalent and physiologically degradable carbohydrate-containing polymers by enzymatic glycosylation reactions and the use thereof for preparing carbohydrate building blocks
EP0601417A3 (de) * 1992-12-11 1998-07-01 Hoechst Aktiengesellschaft Physiologisch verträglicher und physiologisch abbaubarer, Kohlenhydratrezeptorblocker auf Polymerbasis, ein Verfahren zu seiner Herstellung und seine Verwendung
US6300113B1 (en) * 1995-11-21 2001-10-09 New England Biolabs Inc. Isolation and composition of novel glycosidases
DE4408248A1 (de) * 1994-03-11 1995-09-14 Hoechst Ag Physiologisch verträgliche und physiologisch abbaubare Kohlenhydrat-Mimetika, ein Verfahren zur Herstellung und ihre Verwendung
US5679769A (en) * 1994-03-15 1997-10-21 Sloan-Kettering Institute For Cancer Research Synthesis of asparagine-linked glycopeptides on a polymeric solid support
WO1995029927A2 (en) * 1994-05-02 1995-11-09 Biomira, Inc. Process for preparation of glycosides of tumor-associated carbohydrate antigens
SK39498A3 (en) * 1995-09-29 1999-01-11 Glycim Oy Synthetic multivalent slex containing polylactosamines and methods for use
DE69737496D1 (de) * 1996-01-30 2007-05-03 Glycomimetics Inc SIALYL-LEWISa UND SIALYL LEWISx EPITOP-ANALOGE
US6841543B1 (en) * 1996-01-31 2005-01-11 President And Fellows Of Harvard College Methods of inhibiting production of T helper type 2 cytokines in human immune cells
WO1997047646A1 (en) * 1996-06-10 1997-12-18 Boren Thomas Helicobacter pylori adhesin binding group antigen
JP4179567B2 (ja) * 1996-07-23 2008-11-12 生化学工業株式会社 新規ラクトサミンオリゴ糖およびその製造方法
JPH1045602A (ja) * 1996-07-31 1998-02-17 Motoyasu Murakami ヘリコバクター・ピロリ接着阻害剤またはインターロイキン−8産生阻害剤
US6902903B1 (en) * 1996-12-19 2005-06-07 Chiron Corporation Helicobacter pylori diagnostics
ZA9811376B (en) * 1997-12-12 1999-06-28 Expression Genetics Inc Biodegradable mixed polymeric micelles for gene delivery
US6410057B1 (en) * 1997-12-12 2002-06-25 Samyang Corporation Biodegradable mixed polymeric micelles for drug delivery
JP4318765B2 (ja) * 1998-04-01 2009-08-26 雪印乳業株式会社 ピロリ菌感染防御剤
KR100460173B1 (ko) * 1998-12-11 2004-12-04 겐 코오포레이션 헬리코박터 파일로리 정착 억제제
US20010051349A1 (en) * 2000-02-17 2001-12-13 Glycominds Ltd. Combinatorial complex carbohydrate libraries and methods for the manufacture and uses thereof
US20030100508A1 (en) * 1999-02-24 2003-05-29 Maryline Simon Carbohydrate epitope mimic compounds and uses thereof
US20060099691A1 (en) * 1999-05-18 2006-05-11 Apicella Michael A Production of complex carbohydrates
AUPQ275799A0 (en) * 1999-09-10 1999-10-07 Luminis Pty Limited Recombinant bacterium expressing an oligosaccharide receptor mimic
FI19992070A (fi) * 1999-09-28 2001-03-28 Jari Natunen Uudet fukosyloidut oligosakkaridit ja menetelmä niiden valmistamiseksi
SE9904581D0 (sv) * 1999-12-15 1999-12-15 A & Science Invest Ab A novel helicobacter pylori-binding substance and use thereof
FI20010118A (fi) * 2001-01-19 2002-07-20 Carbion Oy Uudet helicobacter pylori reseptorit ja niiden käyttö
EP1417965A1 (en) * 2002-11-07 2004-05-12 Vereniging Voor Christelijk Wetenschappelijk Onderwijs C-type lectin binding molecules, identification and uses thereof
CN1997392B (zh) * 2004-05-11 2011-06-01 荷兰健康、福利与体育部部长代表的荷兰国 作为佐剂的脑膜炎奈瑟氏菌lgtB LOS
EP1787128A2 (en) * 2004-07-09 2007-05-23 Amaox, Inc. Immune cell biosensors and methods of using same
WO2006093524A2 (en) * 2004-07-16 2006-09-08 The General Hospital Corporation Antigen-carbohydrate conjugates

Also Published As

Publication number Publication date
WO2001043751A1 (en) 2001-06-21
CN100389773C (zh) 2008-05-28
SE9904581D0 (sv) 1999-12-15
IL150247A0 (en) 2002-12-01
SK8152002A3 (en) 2002-11-06
US20040086514A1 (en) 2004-05-06
NO20022890D0 (no) 2002-06-17
AU783876B2 (en) 2005-12-15
EP1237558A1 (en) 2002-09-11
NO20022890L (no) 2002-08-15
RU2283115C2 (ru) 2006-09-10
AU2418801A (en) 2001-06-25
JP2003517015A (ja) 2003-05-20
CA2392766A1 (en) 2001-06-21
HUP0204243A2 (hu) 2003-03-28
CN1411376A (zh) 2003-04-16
RU2002118703A (ru) 2004-02-20
ZA200204251B (en) 2003-05-28
CZ20021989A3 (cs) 2002-10-16
NZ520111A (en) 2004-08-27
EE200200312A (et) 2003-06-16
PL356329A1 (en) 2004-06-28

Similar Documents

Publication Publication Date Title
HRP20060251B1 (hr) Supstituirani oksazolidinoni i njihova uporaba
IL190220A0 (en) Novel composition and use
EP1223932A4 (en) COMPOUNDS AND METHODS
EP1146790A4 (en) COMPOUNDS AND METHODS
IL150247A0 (en) Novel helicobacter pylori-binding substances and use thereof
HUP0203896A3 (en) Substituted 8-arylquinoline phosphodiesterase-4-inhibitors and use thereof
HUP0103636A3 (en) 2-methyl-thieno-benzodiazepine formulation and its use
HUP0103473A3 (en) Phosphoglycolipid and methods for its use
EG22491A (en) Rest-breaking composition and use thereof
EP1241586A4 (en) CONTENT DELIVERING DEVICE AND CONTENT USING DEVICE
EP1241257A4 (en) TACHYKININ-SIMILAR POLYPEPTIDES AND ITS APPLICATION
EP1243609A4 (en) SUCCINIMIDE COMPOUNDS AND THEIR USE
GB9929581D0 (en) Comjpositions and their use
GB9911606D0 (en) Composition and use
GB9901897D0 (en) Biological material and use thereof
HUP0201800A2 (en) Novel calpains and their use
HUP0105189A3 (en) Organoprotective solutions and their use
GB9930708D0 (en) MUS101 and homologues thereof
GB9916675D0 (en) Enigma-sip and enigma-cell
EG24062A (en) Novel composition and use
IL149638A0 (en) S-allylmercaptoglutathione and uses thereof
GB9909843D0 (en) Compounds and their use
GB0014089D0 (en) Methods and devices
GB9922474D0 (en) Novel composition and use
GB9919000D0 (en) Novel composition and use

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished